MCID: PDT021
MIFTS: 33

Pediatric Osteosarcoma malady

Categories: Cancer diseases, Bone diseases

Aliases & Classifications for Pediatric Osteosarcoma

Aliases & Descriptions for Pediatric Osteosarcoma:

Name: Pediatric Osteosarcoma 12 14
Childhood Osteosarcoma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3361
NCIt 47 C6585
UMLS 69 C1332986

Summaries for Pediatric Osteosarcoma

MalaCards based summary : Pediatric Osteosarcoma, also known as childhood osteosarcoma, is related to cono-spondylar dysplasia and houlston ironton temple syndrome. An important gene associated with Pediatric Osteosarcoma is SLC19A1 (Solute Carrier Family 19 Member 1), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Folate Metabolism. The drugs Etoposide and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone, and related phenotypes are growth/size/body region and mortality/aging

Related Diseases for Pediatric Osteosarcoma

Graphical network of the top 20 diseases related to Pediatric Osteosarcoma:



Diseases related to Pediatric Osteosarcoma

Symptoms & Phenotypes for Pediatric Osteosarcoma

MGI Mouse Phenotypes related to Pediatric Osteosarcoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.43 IGFBP3 MTHFR ROCK1 SLC19A1 FOLR1 HK2
2 mortality/aging MP:0010768 9.1 DHFR FOLR1 HK2 MTHFR ROCK1 SLC19A1

Drugs & Therapeutics for Pediatric Osteosarcoma

Drugs for Pediatric Osteosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 3,Phase 1,Phase 2 33419-42-0 36462
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Mesna Approved Phase 3,Phase 1,Phase 2 3375-50-6 598
4
Melphalan Approved Phase 3,Phase 1,Phase 2 148-82-3 4053 460612
5
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
6
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
7
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
8
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
9
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
10
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
11
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
12
Busulfan Approved, Investigational Phase 3,Phase 1 55-98-1 2478
13
Zoledronic acid Approved Phase 3,Phase 1 118072-93-8 68740
14
Peginterferon alfa-2b Approved Phase 3 99210-65-8, 215647-85-1
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
16
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 54575, 6560146 143
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
18 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
19 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
20 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
21 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
22 Antirheumatic Agents Phase 3,Phase 1,Phase 2,Early Phase 1
23 Etoposide phosphate Phase 3,Phase 1,Phase 2
24 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
25 Protective Agents Phase 3,Phase 2
26 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
27 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
28 Antiviral Agents Phase 3,Phase 2,Phase 1
29 Antimetabolites Phase 3,Phase 2,Phase 1
30 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
31 Antimitotic Agents Phase 3,Phase 2,Phase 1
32 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
33 Dermatologic Agents Phase 3,Phase 2
34 Folic Acid Antagonists Phase 3,Phase 2
35 Isophosphamide mustard Phase 3,Phase 2,Phase 1
36 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
37 razoxane Phase 3
38 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
39 Vitamin B Complex Phase 3,Phase 2,Phase 1
40 Bone Density Conservation Agents Phase 3,Phase 2,Phase 1
41 Antibodies Phase 3,Phase 2,Phase 1
42 Antibodies, Monoclonal Phase 3,Phase 1,Phase 2
43 Immunoglobulins Phase 3,Phase 2,Phase 1
44 interferons Phase 3,Phase 1
45 Diphosphonates Phase 3,Phase 1
46
Treosulfan Phase 3 299-75-2 9296
47 Keratolytic Agents Phase 3
48 Podophyllotoxin Phase 3 518-28-5
49 Interferon-alpha Phase 3
50 Folate Nutraceutical Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 95)
id Name Status NCT ID Phase
1 Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study Completed NCT00001217 Phase 3
2 Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma Completed NCT00003937 Phase 3
3 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3
4 Study in Localized and Disseminated Ewing Sarcoma Recruiting NCT00987636 Phase 3
5 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3
6 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Recruiting NCT02306161 Phase 3
7 Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Active, not recruiting NCT00134030 Phase 3
8 Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma Unknown status NCT01216826 Phase 2
9 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2
10 Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas Unknown status NCT00998361 Phase 2
11 Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies Completed NCT00038207 Phase 2
12 Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy Completed NCT00035620 Phase 2
13 Clinical Studies of Gemcitabine-Oxaliplatin Completed NCT00407433 Phase 2
14 A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS) Completed NCT02441309 Phase 2
15 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2
16 A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone Completed NCT01288573 Phase 1, Phase 2
17 A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas Completed NCT00001564 Phase 2
18 A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas Completed NCT00001566 Phase 2
19 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2
20 Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor Completed NCT00055952 Phase 2
21 Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas Completed NCT00165139 Phase 2
22 Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas Completed NCT00003745 Phase 2
23 Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma Completed NCT02546544 Phase 2
24 Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma Recruiting NCT02470091 Phase 2
25 A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma Recruiting NCT03006848 Phase 2
26 Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Patients With High-grade, Operable, Non-metastatic Osteosarcoma of the Extremity Recruiting NCT02273583 Phase 2
27 To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Recruiting NCT01962103 Phase 1, Phase 2
28 Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma Recruiting NCT02945800 Phase 2
29 Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors Recruiting NCT02689336 Phase 2
30 Methionine PET/CT Studies In Patients With Cancer Recruiting NCT00840047 Phase 2
31 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors Recruiting NCT02541604 Phase 1, Phase 2
32 Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) Recruiting NCT02624388 Phase 2
33 A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma Recruiting NCT02748135 Phase 1, Phase 2
34 Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors Recruiting NCT02574728 Phase 2
35 Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma Recruiting NCT01864109 Phase 2
36 A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma Recruiting NCT02511132 Phase 2
37 Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma Active, not recruiting NCT01650090 Phase 2
38 A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung Active, not recruiting NCT00752206 Phase 2
39 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Active, not recruiting NCT01614795 Phase 2
40 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Active, not recruiting NCT00667342 Phase 2
41 Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors Active, not recruiting NCT01807468 Phase 2
42 Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma Active, not recruiting NCT02487979 Phase 2
43 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2
44 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma Active, not recruiting NCT00923351 Phase 1, Phase 2
45 Radiation Therapy to Treat Musculoskeletal Tumors Active, not recruiting NCT00186992 Phase 2
46 Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma Suspended NCT02484443 Phase 2
47 Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma Terminated NCT01313884 Phase 2
48 Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma Unknown status NCT00101309 Phase 1
49 Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients Completed NCT01169584 Phase 1
50 Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors Completed NCT00093821 Phase 1

Search NIH Clinical Center for Pediatric Osteosarcoma

Genetic Tests for Pediatric Osteosarcoma

Anatomical Context for Pediatric Osteosarcoma

MalaCards organs/tissues related to Pediatric Osteosarcoma:

39
Bone

Publications for Pediatric Osteosarcoma

Articles related to Pediatric Osteosarcoma:

(show top 50) (show all 70)
id Title Authors Year
1
Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma. ( 27104192 )
2016
2
Efficacy of pamidronate in pediatric osteosarcoma patients with low bone mineral density. ( 27104175 )
2016
3
Novel insights and therapeutic interventions for pediatric osteosarcoma. ( 27651036 )
2016
4
CUL4A expression in pediatric osteosarcoma tissues and its effect on cell growth in osteosarcoma cells. ( 26715273 )
2016
5
The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma. ( 26603261 )
2016
6
Pharmacological or genetic inhibition of LDHA reverses tumor progression of pediatric osteosarcoma. ( 27261617 )
2016
7
Multimodality Imaging in Pediatric Osteosarcoma in the Era of Image Gently and Image Wisely Campaign With a Close Look at the CT Scan Radiation Dose. ( 26583624 )
2016
8
Bone mineral density change during adjuvant chemotherapy in pediatric osteosarcoma. ( 26512351 )
2015
9
PI3K/Akt signaling mediated Hexokinase-2 expression inhibits cell apoptosis and promotes tumor growth in pediatric osteosarcoma. ( 26116768 )
2015
10
Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. ( 25520112 )
2014
11
In silico functional analyses and discovery of survival-associated microRNA signatures in pediatric osteosarcoma. ( 25594070 )
2014
12
Experience of Pediatric Osteosarcoma of the Extremity at a Single Institution in Taiwan: Prognostic Factors and Impact on Survival. ( 25323470 )
2014
13
Management of local recurrence of pediatric osteosarcoma following limb-sparing surgery. ( 24558066 )
2014
14
Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. ( 24703847 )
2014
15
Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma. ( 24038809 )
2014
16
Pediatric Osteosarcoma: A Single Institution's Experience. ( 25365431 )
2014
17
Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature. ( 24667129 )
2014
18
Bronchioloalveolar carcinoma as a second malignancy in a pediatric osteosarcoma survivor: case report. ( 23758793 )
2013
19
Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. ( 23430441 )
2013
20
Pathological fracture as the presenting feature in pediatric osteosarcoma. ( 23281226 )
2013
21
Combined MicroRNA-340 and ROCK1 mRNA Profiling Predicts Tumor Progression and Prognosis in Pediatric Osteosarcoma. ( 24398981 )
2013
22
Endothelin-1 gene polymorphisms and risk of chemoresistant pediatric osteosarcoma. ( 24123836 )
2013
23
Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. ( 23621194 )
2013
24
Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma. ( 22652833 )
2012
25
Plasma proteomic profiling of pediatric osteosarcoma. ( 22083817 )
2012
26
Serum tumor markers in pediatric osteosarcoma: a summary review. ( 22587902 )
2012
27
Correlation of non-mass-like abnormal MR signal intensity with pathological findings surrounding pediatric osteosarcoma and Ewing's sarcoma. ( 22406919 )
2012
28
Case-parent analysis of variation in pubertal hormone genes and pediatric osteosarcoma: a Children's Oncology Group (COG) study. ( 23205180 )
2012
29
Elevated expression of CXC chemokines in pediatric osteosarcoma patients. ( 20806347 )
2011
30
Two pediatric osteosarcoma cases with delayed methotrexate excretion: its clinical course and management. ( 21509165 )
2011
31
Survival outcomes of pediatric osteosarcoma and Ewing's sarcoma: a comparison of surgery type within the SEER database, 1988-2007. ( 22223058 )
2011
32
Primary pediatric osteosarcoma of the skull. ( 22134292 )
2011
33
Location of pulmonary metastasis in pediatric osteosarcoma is predictive of outcome. ( 21763830 )
2011
34
Lengthening of intercalary allograft combined with free vascularized fibular graft after reconstruction in pediatric osteosarcoma of femur. ( 19950438 )
2010
35
Staged lengthening arthroplasty for pediatric osteosarcoma around the knee. ( 19885713 )
2010
36
Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective. ( 20949591 )
2010
37
Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. ( 20734401 )
2010
38
Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. ( 19159907 )
2009
39
Proteomic analysis of chemonaive pediatric osteosarcomas and corresponding normal bone reveals multiple altered molecular targets. ( 19492781 )
2009
40
Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma. ( 18061933 )
2008
41
Clinical characteristics and treatment results of pediatric osteosarcoma: the role of high dose chemotherapy with autologous stem cell transplantation. ( 19688126 )
2008
42
Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. ( 17710657 )
2007
43
The cause and clinical significance of central tumor photopenia on thallium scintigraphy of pediatric osteosarcoma of the extremity. ( 17242270 )
2007
44
Treatment results of pediatric osteosarcoma: twenty-year experience. ( 17314654 )
2007
45
Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. ( 18090928 )
2007
46
KIT gene in pediatric osteosarcomas: could it be a new therapeutic target? ( 17294449 )
2007
47
Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. ( 16673437 )
2006
48
Tumor necrosis in pediatric osteosarcoma: impact of modern therapies. ( 16766682 )
2006
49
Pediatric osteosarcoma: a 35-year experience in Slovenia. ( 16020121 )
2005
50
Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas. ( 15900593 )
2005

Variations for Pediatric Osteosarcoma

Expression for Pediatric Osteosarcoma

Search GEO for disease gene expression data for Pediatric Osteosarcoma.

GO Terms for Pediatric Osteosarcoma

Biological processes related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 axon regeneration GO:0031103 9.26 DHFR FOLR1
2 tetrahydrofolate metabolic process GO:0046653 9.16 DHFR MTHFR
3 folic acid transport GO:0015884 8.96 FOLR1 SLC19A1
4 folic acid metabolic process GO:0046655 8.92 DHFR FOLR1 MTHFR SLC19A1

Molecular functions related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.32 DHFR FOLR1
2 NADP binding GO:0050661 9.26 DHFR MTHFR
3 folic acid transporter activity GO:0008517 9.16 FOLR1 SLC19A1
4 methotrexate binding GO:0051870 8.96 DHFR FOLR1
5 folic acid binding GO:0005542 8.8 DHFR FOLR1 SLC19A1

Sources for Pediatric Osteosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....